Chronic rhinosinusitis in people with Cystic Fibrosis: Expanding evidence and future directions

Published:August 05, 2022DOI:
      Chronic rhinosinusitis (CRS) is a prevalent and impactful disease complication for people with CF (CF). Longstanding upper airway inflammation associated with CRS decreases quality of life (QOL), is associated with productivity loss, adversely impacts pulmonary status, and impairs olfaction. Given recent advances that have improved longevity for individuals with CF, directed management of extrapulmonary manifestations of CF such as CRS is increasingly important to people with CF.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Cystic Fibrosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Rosenfeld R.M.
        • Piccirillo J.F.
        • Chandrasekhar S.S.
        • et al.
        Clinical practice guideline (update): adult sinusitis.
        Otolaryngol Head Neck Surg. 2015; 152: S1-S39
        • Okafor S.
        • Kelly K.M.
        • Halderman A.A.
        Management of Sinusitis in the Cystic Fibrosis patient.
        Immunol Allergy Clin North Am. 2020; 40: 371-383
      1. Cystic Fibrosis Foundation Patient Registry.
        Annual Data Report, 2020: 96 (2020)
        • Lee D.J.
        • Sykes J.
        • al G.K.
        The negative impact of chronic rhinosinusitis on the health-related quality of life among adult patients with Cystic Fibrosis.
        J Cyst Fibros. 2022;
        • Stapleton A.L.
        • Kimple A.J.
        • Goralski J.L.
        • et al.
        Elexacaftor-Tezacaftor- Ivacaftor improves sinonasal outcomes in Cystic Fibrosis.
        J Cyst Fibros. 2022;
        • Kimple A.J.
        • Senior B.A.
        • Naureckas E.T.
        • et al.
        Cystic Fibrosis Foundation otolaryngology care multidisciplinary consensus recommendations.
        Int Forum Allergy Rhinol. 2022;
        • Rudmik L.
        • Soler Z.M.
        • Smith T.L.
        • Mace J.C.
        • Schlosser R.J.
        • DeConde AS.
        Effect of continued medical therapy on productivity costs for refractory chronic rhinosinusitis.
        JAMA Otolaryngol Head Neck Surg. 2015; 141: 969-973
        • DiMango E.
        • Overdevest J.
        • Keating C.
        • Francis S.F.
        • Dansky D.
        • Gudis D.
        Effect of highly effective modulator treatment on sinonasal symptoms in Cystic Fibrosis.
        J Cyst Fibros. 2021; 20: 460-463
        • Beswick D.M.
        • Humphries S.M.
        • Balkissoon C.D.
        • et al.
        Impact of CFTR therapy on chronic rhinosinusitis and health status: deep learning ct analysis and patient reported outcomes.
        Ann Am Thorac Soc. 2022; 19: 12-19
        • Wucherpfennig L.
        • Triphan S.M.F.
        • al W.S.
        Magnetic resonance imaging detects improvements of pulmonary and paranasal sinus abnormalities in response to elexacaftor/tezacaftor/ivacaftor therapy in adults with Cystic Fibrosis.
        J Cyst Fibros. 2022;
        • Beswick D.M.
        • Humphries S.M.
        • Balkissoon C.D.
        • et al.
        Olfactory dysfunction in Cystic Fibrosis: impact of CFTR modulator therapy.
        J Cyst Fibros. 2021;
        • Bacon D.R.
        • Stapleton A.
        • Goralski J.L.
        • et al.
        Olfaction before and after initiation of elexacaftor-tezacaftor-ivacaftor in a Cystic Fibrosis cohort.
        Int Forum Allergy Rhinol. 2022; 12: 223-226
        • Castellanos C.X.
        • Osterbauer B.
        • Hasday S.
        • Keens T.G.
        • Koempel J.
        • Ference E.H.
        Improvement in sinonasal quality-of-life indicators for pediatric patients with Cystic Fibrosis treated with elexacaftor-tezacaftor-ivacaftor.
        Int Forum Allergy Rhinol. 2022;
      2. Impact of Sinus Surgery on Individuals With Cystic Fibrosis, NCT04469439. Available at: Accessed 16 July 2022.

        • Ramos K.J.
        • Guimbellot J.S.
        • al V.M.
        Use of elexacaftor/tezacaftor/ivacaftor among Cystic Fibrosis lung transplant recipients.
        J Cyst Fibros. 2022;